Viridian Therapeutics, Inc. VRDN Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s net unrealized gains (losses) on securities still held?
- Viridian Therapeutics, Inc. (VRDN) reported net unrealized gains (losses) on securities still held of -$1.01M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s net unrealized gains (losses) on securities still held changed year-over-year?
- Viridian Therapeutics, Inc.'s net unrealized gains (losses) on securities still held decreased by 495.3% year-over-year, from $255K to -$1.01M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s net unrealized gains (losses) on securities still held?
- Over 2 years (2023 to 2025), Viridian Therapeutics, Inc.'s net unrealized gains (losses) on securities still held has grown at a -20.8% compound annual growth rate (CAGR), from $728K to $457K.
- What does net unrealized gains (losses) on securities still held mean?
- This metric represents the change in the fair value of available-for-sale debt securities held by the company that have not yet been realized through a sale. It captures unrealized gains or losses that are excluded from net income and instead reported as a component of other comprehensive income. Monitoring this figure helps investors understand the impact of market interest rate fluctuations on the company's investment portfolio.